Geron Highlights RYTELO Launch, 2026 Revenue Outlook and Phase 3 Myelofibrosis Plans at Needham Conf [Yahoo! Finance]
Geron Corporation (GERN)
Last geron corporation earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
geron.com/investors
Company Research
Source: Yahoo! Finance
guidance of $220–$240 million for 2026 and citing about $400 million on its balance sheet while focusing commercial efforts on high-volume accounts and digital promotion. U.S. adoption requires significant physician education because early, predictable cytopenias (typically recovering in 2–4 weeks in 80% of patients) are viewed as an on-target effect that correlates with durable response; Geron positions imetelstat preferentially as second-line per NCCN and as a first-line option for ESA-ineligible patients. The IMpactMF Phase 3 myelofibrosis trial is a 2:1 randomized study with overall survival as the primary endpoint , with an interim analysis expected in H2 and the company holding worldwide rights (including EMA approval) while evaluating ex-U.S. commercialization and potential partnerships. Interested in Geron Corporation? Here are five stocks we like better. Geron Corporation: FDA Approval Fuels Stock Price Surge Geron (NASDAQ:GERN) executives used a presentation at the
Show less
Read more
Impact Snapshot
Event Time:
GERN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GERN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GERN alerts
High impacting Geron Corporation news events
Weekly update
A roundup of the hottest topics
GERN
News
- Geron Adds Chief Legal Officer As Equity Ties To Execution Risk [Yahoo! Finance]Yahoo! Finance
- Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Geron Announces Appointment of Timothy Williams as Executive Vice President, Chief Legal Officer and Corporate SecretaryGlobeNewswire
- Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Geron to Participate in the 25th Annual Needham Virtual Healthcare ConferenceGlobeNewswire
GERN
Earnings
- 2/25/26 - Miss
GERN
Sec Filings
- 4/14/26 - Form 4
- 4/14/26 - Form 3
- 4/7/26 - Form ARS
- GERN's page on the SEC website